CAUTIONARY REGARDING FORWARD-LOOKING STATEMENTS

We may make statements that are not historical facts and relate to analyses and other information based on forecasts of future results and estimates of amounts not yet determinable. These are forward looking statements as defined in the U.S. Private Securities Litigation Reform Act of 1995. Words such as “prospects”, “believe”, “anticipate”, “expect”, “intend”, “seek”, “will”, “plan”, “indicate”, “could”, “may”, “endeavour” and “project” and similar expressions are intended to identify such forward looking statements but are not the exclusive means of identifying such statements. By their very nature, forward-looking statements involve inherent risks and uncertainties, both general and specific, and there are risks that predictions, forecasts, projections and other forward-looking statements will not be achieved. If one or more of these risks materialise, or should underlying assumptions prove incorrect, actual results may be very different from those anticipated. The factors that could cause our actual results to differ materially from the plans, objectives, expectations, estimates and intentions expressed in such forward-looking statements are discussed in each year’s annual report.

Forward looking statements apply only as of the date on which they are made, and we do not undertake, other than in terms of the Listings Requirements of the JSE Limited, any obligation to update or revise any of them, whether as a result of new information, future events or otherwise. Any profit forecasts published in this report are unaudited and have not been reviewed or reported on by Aspen's external auditors.
The Group has revised its reportable segments to reflect the newly updated operating model, which aligns to the way in which the business is managed and reported on by the Chief Operating Decision Maker (“CODM”). The business segments that make up the Manufacturing segment have been revised to align to the Group’s capacity fill and manufacturing strategy. The updated business segments are set out below:

- **Active Pharmaceutical Ingredients ("API")** – this segment includes the API Chemicals business and non-heparin biochemical API business.

- **Heparin** – this segment includes the full value chain contribution from all heparin containing products including API and Finished Dose Form ("FDF") sales. Key products include the Fraxiparine and MonoEmbolex heparin containing FDF products as well as the sale of heparin API to third parties.

- **FDF Steriles** – this segment includes all FDF sterile sales and will be the key growth driver supporting the Group’s medium term capacity fill objectives. This segment excludes all heparin based prefilled syringes which are included in the heparin business segment.

- **FDF Other** – this segment includes all non-sterile FDF products.
**TRADING ENVIRONMENT**

**TESTING ENVIRONMENTAL FACTORS PERSISTED**

<table>
<thead>
<tr>
<th></th>
<th>H1 2022</th>
<th>H2 2022</th>
<th>H1 2023</th>
</tr>
</thead>
<tbody>
<tr>
<td>Russia/ Ukraine War</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>China Headwinds</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>COVID Vaccine Demand</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Material Divestment</td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

- Russia/ Ukraine War: Business interruption, Spiralling inflation
- China Headwinds: COVID lockdowns, Volume based procurement
- COVID Vaccine Demand: J&J production ended, No Aspenovax offtake
- Material Divestment: Product portfolio divested in South Africa

**POSITIVE STRATEGIC DEVELOPMENTS GAINING MOMENTUM**

- High demand for pre-filled syringe production to support innovator product plans
- Commitment to Africa-manufactured pharmaceuticals for African requirements
- Resilient and effective sales footprint across extensive geographies
- Realignment of Pharma companies creating product portfolio opportunities
PERFORMANCE OVERVIEW

H1 2023

- H1 2023 in line with guidance
- Resilient Commercial Pharma performance in spite of China, Russia and product divestments
- Commercial Pharma gross margin expansion is a major achievement considering headwinds
  » Strong brand equity
- Carried significant costs in Manufacturing
  » Additional overheads required to be absorbed following the end of COVID vaccine production
  » Introduction of numerous product trials across major facilities which are critical to ensuring timeous future revenue streams
    • Evidenced by the advancement of material contracts
    • Grants from Gates Foundation and CEPI offset some of the technical transfer costs related to Serum Institute of India (SII) vaccines
- Operating expenses kept under control despite rampant inflation
- Earnings knock from forex losses (R284 million swing from a year ago)
- Technical transfer of SII vaccines well on track
  » Subject to regulatory approvals, sales expected in H2 of FY 2024
- Transactions to build on Commercial Pharma well advanced
- Excellent progress on capacity fill contracting
  » Most critical internal KPI
  » Material, sustainable and predictable earnings generator
Adjusting for SA divestment, Reported Group revenue flat, Commercial Pharma +4% and Regional Brands +11%

Commercial Pharma growth driven by strong organic growth from Regional Brands in most territories with some offset from:
- China (COVID lockdowns, VBP) and Russia (Ukraine war)

Loss of COVID vaccine and capacity allocation to new product trials weighed on Manufacturing

Commercia Pharma revenue +9% (+4% CER) vs H2 of prior year

Positive exchange rate tailwinds benefited Reported revenue

---

1  CER removes the currency effect on performance. H1 2022 has been restated at H1 2023 average exchange rates.
### Revenue

<table>
<thead>
<tr>
<th>Region</th>
<th>H1 2023</th>
<th>H1 2022</th>
<th>% Change Reported</th>
<th>% Change CER</th>
</tr>
</thead>
<tbody>
<tr>
<td>Africa Middle East</td>
<td>3 885</td>
<td>3 961</td>
<td>-2%</td>
<td>-3%</td>
</tr>
<tr>
<td>Australasia</td>
<td>2 588</td>
<td>2 303</td>
<td>12%</td>
<td>7%</td>
</tr>
<tr>
<td>Americas</td>
<td>1 673</td>
<td>1 361</td>
<td>23%</td>
<td>7%</td>
</tr>
<tr>
<td>Europe CIS</td>
<td>858</td>
<td>803</td>
<td>7%</td>
<td>4%</td>
</tr>
<tr>
<td>Asia</td>
<td>351</td>
<td>299</td>
<td>17%</td>
<td>8%</td>
</tr>
<tr>
<td><strong>Regional Brands</strong></td>
<td><strong>9 355</strong></td>
<td><strong>8 727</strong></td>
<td><strong>7%</strong></td>
<td><strong>2%</strong></td>
</tr>
</tbody>
</table>

- Regional Brands maintained positive momentum in spite of divestment
- Excluding impact of divestment from South African performance
  - Africa Middle East +6% (+5% CER) & Regional Brands +11% (+6% CER)
- Exceptional performance in Australia built on strong service delivery
- Latin American teams continues to sustain historic growth trajectory

---

*CER removes the currency effect on performance. H1 2022 has been restated at H1 2023 average exchange rates.*
### REVENUE

<table>
<thead>
<tr>
<th>Region</th>
<th>H1 2023</th>
<th>H1 2022</th>
<th>% change</th>
<th>CER(^1)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Asia</td>
<td>2 277</td>
<td>2 426</td>
<td>-6%</td>
<td>-12%</td>
</tr>
<tr>
<td>Europe CIS</td>
<td>1 585</td>
<td>1 795</td>
<td>-12%</td>
<td>-18%</td>
</tr>
<tr>
<td>Americas</td>
<td>760</td>
<td>718</td>
<td>6%</td>
<td>-6%</td>
</tr>
<tr>
<td>Australasia</td>
<td>363</td>
<td>353</td>
<td>3%</td>
<td>-2%</td>
</tr>
<tr>
<td>Africa Middle East</td>
<td>207</td>
<td>242</td>
<td>-14%</td>
<td>-17%</td>
</tr>
<tr>
<td><strong>Sterile Focus Brands</strong></td>
<td><strong>5 192</strong></td>
<td><strong>5 534</strong></td>
<td><strong>-6%</strong></td>
<td><strong>-13%</strong></td>
</tr>
</tbody>
</table>

- China & Russia impacted Steriles
  - Russia: Allocation of funding to the Ukraine war effort has severely diminished healthcare spending
  - China: COVID lockdowns & Naropin VBP impact
    - Lockdowns now lifted

\(^1\) CER removes the currency effect on performance. H1 2022 has been restated at H1 2023 average exchange rates.
**MANUFACTURING**

**REVENUE**

<table>
<thead>
<tr>
<th>R’million</th>
<th>H1 2023</th>
<th>H1 2022</th>
<th>% change</th>
</tr>
</thead>
<tbody>
<tr>
<td>API</td>
<td>2,034</td>
<td>2,222</td>
<td>-8%</td>
</tr>
<tr>
<td>Heparin</td>
<td>1,107</td>
<td>1,087</td>
<td>2%</td>
</tr>
<tr>
<td>FDF - Steriles</td>
<td>809</td>
<td>1,277</td>
<td>-37%</td>
</tr>
<tr>
<td>FDF - Other</td>
<td>653</td>
<td>534</td>
<td>22%</td>
</tr>
<tr>
<td><strong>Manufacturing</strong></td>
<td><strong>4,603</strong></td>
<td><strong>5,120</strong></td>
<td><strong>-10%</strong></td>
</tr>
</tbody>
</table>

- API – Lost one month of production due to strategic maintenance programme
  - Occurs every 5 years
- New product initiation impacted production downtime
  - Heparin revenue constrained
- FDF Steriles – Termination of COVID production, with some offset from NDB sterile offtakes
- Much stronger H2 expected driven by:
  - API & Heparin

1. CER removes the currency effect on performance. H1 2022 has been restated at H1 2023 average exchange rates.
CREDITABLE HALF YEAR PERFORMANCE IN LIGHT OF GUIDED HEADWINDS

FINANCIAL HIGHLIGHTS

-6% CER\(^i\)

\[\begin{array}{c|c|c|c}
\text{H1 2022} & 19,381 \text{ (R'million)} & 48.5\% & 5,716 \\
\text{H2 2022} & 19,225 & 46.4\% & 5,296 \\
\text{H1 2023} & 19,150 & 46.8\% & 5,083 \\
\end{array}\]

Revenue (R'million)

-1% CER\(^i\)

\[\begin{array}{c|c|c|c}
\text{H2 2022} & 19,225 & 46.4\% & 5,296 \\
\text{H1 2023} & 19,150 & 46.8\% & 5,083 \\
\end{array}\]

Gross Profit Margin %

11% CER\(^i\)

\[\begin{array}{c|c|c|c}
\text{H1 2023} & 19,150 & 46.8\% & 5,083 \\
\end{array}\]

Normalised EBITDA\(^\wedge\)

15% CER\(^i\)

\[\begin{array}{c|c|c|c}
\text{H1 2023} & 19,150 & 46.8\% & 5,083 \\
\end{array}\]

Normalised Headline Earnings per share\(^\Sigma\) (cents)

21% CER\(^i\)

\[\begin{array}{c|c|c|c}
\text{H1 2023} & 19,150 & 46.8\% & 5,083 \\
\end{array}\]

\(^*\) Percentage points.

\(^\wedge\) Normalised EBITDA represents operating profit before depreciation and amortisation adjusted for specific non-trading items as defined in the Group’s accounting policy.

\(^\Sigma\) Normalised headline earnings per share is headline earnings per share adjusted for specific non-trading items as defined in the Group’s accounting policy.

\(^i\) CER removes the currency effect on performance. H1 2022 has been restated at H1 2023 average exchange rates.
## NORMALISED EBITDA

<table>
<thead>
<tr>
<th>R'million</th>
<th>H1 2023</th>
<th>% of revenue</th>
<th>H1 2022</th>
<th>% of revenue</th>
<th>% change</th>
<th>% change CER(^*)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Revenue</td>
<td>19 150</td>
<td>100.0%</td>
<td>19 381</td>
<td>100.0%</td>
<td>-1%</td>
<td>-6%</td>
</tr>
<tr>
<td>Gross profit(^*)</td>
<td>8 966</td>
<td>46.8%</td>
<td>9 395</td>
<td>48.5%</td>
<td>-5%</td>
<td>-9%</td>
</tr>
<tr>
<td>Depreciation</td>
<td>594</td>
<td>3.1%</td>
<td>582</td>
<td>3.0%</td>
<td>2%</td>
<td>-1%</td>
</tr>
<tr>
<td>Operating expenses</td>
<td>(4 621)</td>
<td>24.1%</td>
<td>(4 287)</td>
<td>22.1%</td>
<td>8%</td>
<td>3%</td>
</tr>
<tr>
<td>Net other operating income</td>
<td>144</td>
<td>0.8%</td>
<td>26</td>
<td>0.1%</td>
<td>&gt;100%</td>
<td>&gt;100%</td>
</tr>
<tr>
<td><strong>Normalised EBITDA</strong></td>
<td><strong>5 083</strong></td>
<td><strong>26.5%</strong></td>
<td><strong>5 716</strong></td>
<td><strong>29.5%</strong></td>
<td><strong>-11%</strong></td>
<td><strong>-15%</strong></td>
</tr>
</tbody>
</table>

Prior period included pre-war Russian sales, no China lockdown or VBP\(^*\) and SA products subsequently divested

Improved Commercial Pharma margins through cost of goods initiatives were more than offset by reduced Manufacturing gross profit largely from the loss of vaccine revenue. This negatively impacted gross margin, EBITDA and margin %

Tightly controlled expenses given inflationary environment

---

\(^*\) CER removes the currency effect on performance. H1 2022 has been restated at H1 2023 average exchange rates.

\(^*\) Gross profit is after deduction of depreciation.

\(^*\) Volume Based Procurement
GROSS PROFIT PERCENTAGE
CER\(^1\) AT H1 2023 RATES

**Regional Brands**
Favourable sales mix and cost of goods initiatives increase margins amidst inflationary headwinds

<table>
<thead>
<tr>
<th></th>
<th>FY 2021</th>
<th>H1 2022</th>
<th>H2 2022</th>
<th>H1 2023</th>
</tr>
</thead>
<tbody>
<tr>
<td>54.9%</td>
<td>57.0%</td>
<td>56.5%</td>
<td>59.7%</td>
<td></td>
</tr>
</tbody>
</table>

**Sterile Focus Brands**
Site transfer savings improve margins above H2 2022. Positive trajectory versus FY 2021 even after the China Naropin VBP\(^*\) impact

<table>
<thead>
<tr>
<th></th>
<th>FY 2021</th>
<th>H1 2022</th>
<th>H2 2022</th>
<th>H1 2023</th>
</tr>
</thead>
<tbody>
<tr>
<td>60.0%</td>
<td>61.4%</td>
<td>59.0%</td>
<td>60.5%</td>
<td></td>
</tr>
</tbody>
</table>

**Manufacturing**
Loss of vaccine contribution, lower sales high margin APIs coupled with non-revenue generating sterile technical transfer costs and inflationary pressure reduce margins

<table>
<thead>
<tr>
<th></th>
<th>FY 2021</th>
<th>H1 2022</th>
<th>H2 2022</th>
<th>H1 2023</th>
</tr>
</thead>
<tbody>
<tr>
<td>19.5%</td>
<td>19.2%</td>
<td>20.2%</td>
<td>5.2%</td>
<td></td>
</tr>
</tbody>
</table>

**Group**
Improved Commercial Pharma margins outweighed by lower Manufacturing contribution. Margins are favourably ahead of H2 2022

<table>
<thead>
<tr>
<th></th>
<th>FY 2021</th>
<th>H1 2022</th>
<th>H2 2022</th>
<th>H1 2023</th>
</tr>
</thead>
<tbody>
<tr>
<td>47.5%</td>
<td>48.6%</td>
<td>46.1%</td>
<td>46.8%</td>
<td></td>
</tr>
</tbody>
</table>

\(^1\) CER removes the currency effect on performance. H1 2022 has been restated at H1 2023 average exchange rates.

\(^*\) Volume Based Procurement
FOREX LOSSES HAVE MORE THAN OFFSET REDUCTION IN NET INTEREST PAID

Aspen H2 2023 effective interest rates are expected to be cushioned to an increase of between 60 to 80 basis points because of the 0% fixed base rate IFC loan (EUR 600 million) combined with expected lower second half debt levels. Without the protection of the IFC loan, base rates would have increased by up to 180 basis points.

High foreign exchange losses driven by a weakening of emerging market currencies against the EUR and USD, primarily relating to trading working capital balances.

*Excluding amortisation of capital raising fees.
MANUFACTURING INVENTORY LEVELS EXPECTED TO REDUCE IN H2 2023

- Strategic inventory stock build following COVID led supply chain disruptions and inflation. Reductions expected from CY 2023 onwards following supply chain normalisation.
- API and Heparin segment revenue heavily weighted to H2 2023 with a substantial inventory unwind expected.
- Cash conversion rate targeted to exceed 100% by the financial year end.
- Net working capital % of revenue projected to reduce during H2 2023.

Net working capital % of revenue:

<table>
<thead>
<tr>
<th>Year</th>
<th>H1 2022</th>
<th>FY 2022</th>
<th>H1 2023</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total</td>
<td>45%</td>
<td>51%</td>
<td>42%</td>
</tr>
<tr>
<td>Excluding Oss</td>
<td>38%</td>
<td>38%</td>
<td>42%</td>
</tr>
</tbody>
</table>

*Net working capital % of revenue based on reported rates and not CER.*
WEAKER ZAR AND DIVIDEND OUTFLOWS INCREASE H1 2023 DEBT LEVELS

Leverage ratio well below targeted levels at 2.1x

1 CER removes the currency effect on performance. H1 2022 has been restated at H1 2023 average exchange rates.
ESG, SITE RISK AND MITIGATION
ESG: DELIVERING VALUE THROUGH PURPOSE

HEALTHCARE. WE CARE

Improving health and quality of life for patients that use our medicines

- Access to affordable high-quality medicines across a broad geography including more than 60 low- and middle-income countries

Vaccines for Africa

- Technical projects underway to enhance access to vaccines across Africa through agreement with The Serum Institute of India (SII) supported by CEPI and Gates Foundation grants

Responding to Health and Humanitarian crises

- Several Socio-economic development initiatives, aimed at strengthening healthcare systems and social upliftment, including emergency product donations have been implemented

Emergency Donation

- Medicines and other humanitarian aid donated to assist efforts in the aftermath of the devastating earthquake in Turkey and Syria
Continuity of electricity supply – Gqeberha

Interim measures
- 8% of energy requirements met via solar panels
- Stages 1-4: Currently exempt from loadshedding
- Stages 5 and above: Predetermined schedule with Municipality
- Backup power meets full site electricity needs

Medium term solution
- Plan is to be off the Municipal power supply grid within two years
- Power supply project that converts plastic waste to synthetic gas by pyrolysis and is expected to come online in two years
- Projected lower cost than Eskom

Water Scarcity – South African Sites

- Water conservation practices implemented across sites
- Gqeberha site has no reliance on Municipal water
- Water requirements fully supplied from ground water extraction, treatment and reticulation
- FCC site ground water sufficient to meet production requirement

Energy availability and costs – European Manufacturing Sites

- Diversification of energy sources reduces reliance on any single source of power, including natural gas
- Fixed price contracts mitigate against volatility
PROSPECTS

STRATEGIC GROWTH OBJECTIVES

Commercial Pharma
- Steady organic growth
- Very strong cash generator
- Funded the Manufacturing platform
- Gross margin improvements delivered
  - Despite pricing pressures and inflation
  - Largely driven by Manufacturing cost savings
- Acquisitions to enhance growth

Sterile manufacturing expansion
- Core growth investment initiative over last 5 years
- Successful allocation and utilisation of installed capacity
  - Delivery of manufacturing contracts fundamental
- Incremental growth opportunity given limited added fixed costs
  - Capex largely complete* with opex and personnel also deployed
  - Increasing contribution will drive strong free cash flow

Enhanced ROIC
Strong Free Cash Flows
Capital Allocation optionality

DELIVERY OF MANUFACTURING CONTRACTS AND ENHANCEMENT OF COMMERCIAL PHARMA GROWTH

* = R1 370 million capex remaining
PROSPECTS
COMMERCIAL PHARMA OUTLOOK

Sustained organic growth for commercial brands portfolio

- Diverse product portfolio with strong brand equity supported by in-country commercial and sales employees
- Resilience demonstrated
  - Growing sales
  - Improving margin in spite of pricing pressure

China seen as country with greatest growth potential

- Numerous commercial discussions in progress
- Next 3 years working to mitigate further potential VBP exposure and maximise pipeline
  - Leverage sales force capability with collaboration arrangement
  - Launches from Aspen pipeline development
  - Product acquisitions/licenses

Commercial Pharma portfolio will be expanded

- Targeting to add products in Latin America and South Africa within the next 6 months with revenue of circa USD 100 million
- Build critical mass across Latam
- South African capability to be bolstered/extended by:
  - Multinational relationships
  - Access to new chemical entities and biosimilar pipeline exclusive to Aspen
COVID vaccine production demonstrated value and competence of Aspen’s sterile manufacturing

- Albeit a couple more years were needed to seamlessly integrate with other sterile opportunities
- One of the key catalysts driving contract initiations

Unique positioning for sterile vials, despite global over capacity

- African manufacturing solution for African demand
- Supported by Gavi
- Driving Asian/multi-national behaviour
  - ESG and volume retention opportunity
- Quality, global supply
- Competitive pricing

Significant capacity for pre-filled syringes (“PFS”) immediately available

- Global capacity shortage exacerbated by
  - Big pharma portfolio development shift
  - COVID vials to PFS
  - Diabetic/weight-loss & HIV portfolios
- Increased development and usage of vaccines

Fulfillment of strategic goal will be delivery of returns on the material investment into sterile production

- Filling capacity and optimizing its allocation is key to achieving this objective
MANUFACTURING: CAPACITY FILL PROGRESS

- Crystalized view of capacity value and market dynamics
- Includes vaccines and biologicals
- Four multinationals and Serum
  - Public announcements to follow in due course
  - A number of additional contracts under discussion
- Analytical, feasibility and capability assessments completed
- Tech transfer activities initiated
  - Trial and validation batches
  - Site registration 12-24 months
  - Seasonal bias toward EU winter manufacturing
- Revised upwards to at least R8 billion
- Significant progress made in contract advancement
- R4 billion in agreements advanced/completed

PROSPECTS

CY 2024: R2 billion
CY 2025: R4 billion

Previous estimate of capacity fill was R3 billion in contribution
Revised upwards to at least R8 billion
Significant progress made in contract advancement
R4 billion in agreements advanced/completed

Due diligence reviews completed
- Analytical, feasibility and capability assessments completed
- Tech transfer activities initiated
  - Trial and validation batches
  - Site registration 12-24 months

Proven capability as world class sterile manufacturer
GROUP GUIDANCE

H2 2023

- Guidance on stronger H2 relative to H1 is maintained
- Improved H2 revenue outcome compared to H2 2022 from both Commercial Pharma and Manufacturing
  - Significant H2 Manufacturing growth expected to even overcome loss of COVID vaccine
- Targeting Reported EBITDA for FY 2023 on par with FY 2022
  - Supported by the improved gross profit percentages from Commercial Pharma
- Anticipated weaker ZAR will provide uplift in Reported results
- Rising interest rates will affect finance charges
- Cash flow conversion for year > 100%
- Commercial pharma transactions to be closed
  - Will provide new growth stimulus in Latin America and South Africa
- Manufacturing agreements to be signed
  - Contracts for longer duration and value
## APPENDIX 1 | ABRIDGED STATEMENT OF COMPREHENSIVE INCOME

<table>
<thead>
<tr>
<th></th>
<th>H1 2023 (R’million)</th>
<th>H1 2022 (R’million)</th>
<th>% change</th>
<th>FY 2022 (R’million)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Net revenue</td>
<td>19 150</td>
<td>19 381</td>
<td>-1%</td>
<td>38 606</td>
</tr>
<tr>
<td>Cost of sales</td>
<td>(10 184)</td>
<td>(9 986)</td>
<td>-20%</td>
<td>(20 300)</td>
</tr>
<tr>
<td>Gross profit</td>
<td>8 966</td>
<td>9 395</td>
<td>-5%</td>
<td>18 306</td>
</tr>
<tr>
<td>Gross profit margin</td>
<td>46.8%</td>
<td>48.5%</td>
<td></td>
<td>47.4%</td>
</tr>
<tr>
<td>Operating expenses</td>
<td>(4 621)</td>
<td>(4 287)</td>
<td></td>
<td>(8 539)</td>
</tr>
<tr>
<td>Net other operating expenses</td>
<td>(449)</td>
<td>(550)</td>
<td></td>
<td>(1 096)</td>
</tr>
<tr>
<td>Depreciation</td>
<td>594</td>
<td>582</td>
<td></td>
<td>1 167</td>
</tr>
<tr>
<td>Amortisation</td>
<td>266</td>
<td>270</td>
<td></td>
<td>546</td>
</tr>
<tr>
<td>EBITDA</td>
<td>4 756</td>
<td>5 410</td>
<td>-12%</td>
<td>10 384</td>
</tr>
<tr>
<td>Depreciation</td>
<td>(594)</td>
<td>(582)</td>
<td></td>
<td>(1 167)</td>
</tr>
<tr>
<td>Amortisation</td>
<td>(266)</td>
<td>(270)</td>
<td></td>
<td>(546)</td>
</tr>
<tr>
<td>Operating profit</td>
<td>3 896</td>
<td>4 558</td>
<td>-15%</td>
<td>8 671</td>
</tr>
<tr>
<td>Net funding costs</td>
<td>(598)</td>
<td>(364)</td>
<td></td>
<td>(537)</td>
</tr>
<tr>
<td>Profit before tax</td>
<td>3 298</td>
<td>4 194</td>
<td>-21%</td>
<td>8 134</td>
</tr>
<tr>
<td>Tax</td>
<td>(624)</td>
<td>(834)</td>
<td></td>
<td>(1 646)</td>
</tr>
<tr>
<td>Profit after tax</td>
<td>2 674</td>
<td>3 360</td>
<td>-20%</td>
<td>6 488</td>
</tr>
<tr>
<td>EPS (cents)</td>
<td>602</td>
<td>736</td>
<td>-18%</td>
<td>1 432</td>
</tr>
<tr>
<td>HEPS (cents)</td>
<td>661</td>
<td>777</td>
<td>-15%</td>
<td>1 461</td>
</tr>
<tr>
<td>NHEPS (cents)</td>
<td>680</td>
<td>816</td>
<td>-17%</td>
<td>1 628</td>
</tr>
</tbody>
</table>
### APPENDIX 2 | ABRIDGED STATEMENT OF NORMALISED COMPREHENSIVE INCOME

<table>
<thead>
<tr>
<th></th>
<th>H1 2023</th>
<th>H1 2022</th>
<th>% change</th>
<th>H1 2022 (CER&lt;sup&gt;1&lt;/sup&gt;)</th>
<th>% change (CER&lt;sup&gt;1&lt;/sup&gt;)</th>
<th>FY 2022</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Revenue</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Net revenue</td>
<td>19 150</td>
<td>19 381</td>
<td>-1%</td>
<td>20 323</td>
<td>-6%</td>
<td>38 606</td>
</tr>
<tr>
<td>Cost of sales</td>
<td>(10 184)</td>
<td>(9 986)</td>
<td>2%</td>
<td>(10 456)</td>
<td>-3%</td>
<td>(20 300)</td>
</tr>
<tr>
<td><strong>Gross profit</strong></td>
<td>8 966</td>
<td>9 395</td>
<td>-5%</td>
<td>9 867</td>
<td>-9%</td>
<td>18 306</td>
</tr>
<tr>
<td>Gross profit margin</td>
<td>46.8%</td>
<td>48.5%</td>
<td></td>
<td>48.6%</td>
<td></td>
<td>47.4%</td>
</tr>
<tr>
<td>Operating expenses</td>
<td>(4 621)</td>
<td>(4 287)</td>
<td>8%</td>
<td>(4 500)</td>
<td>3%</td>
<td>(8 539)</td>
</tr>
<tr>
<td>Net other operating income</td>
<td>144</td>
<td>26</td>
<td>&gt;100%</td>
<td>28</td>
<td>&gt;100%</td>
<td>78</td>
</tr>
<tr>
<td>Depreciation</td>
<td>594</td>
<td>582</td>
<td>2%</td>
<td>602</td>
<td>-1%</td>
<td>1 167</td>
</tr>
<tr>
<td><strong>Normalised EBITDA</strong></td>
<td>5 083</td>
<td>5 716</td>
<td>-11%</td>
<td>5 997</td>
<td>-15%</td>
<td>11 012</td>
</tr>
<tr>
<td>EBITDA margin</td>
<td>26.5%</td>
<td>29.5%</td>
<td></td>
<td>29.5%</td>
<td></td>
<td>28.5%</td>
</tr>
<tr>
<td>Depreciation</td>
<td>(594)</td>
<td>(582)</td>
<td>2%</td>
<td>(602)</td>
<td>-1%</td>
<td>(1 167)</td>
</tr>
<tr>
<td>Amortisation</td>
<td>(266)</td>
<td>(270)</td>
<td>-1%</td>
<td>(280)</td>
<td>-5%</td>
<td>(546)</td>
</tr>
<tr>
<td><strong>Operating profit</strong></td>
<td>4 223</td>
<td>4 864</td>
<td>-13%</td>
<td>5 115</td>
<td>-17%</td>
<td>9 299</td>
</tr>
<tr>
<td>Net funding costs</td>
<td>(586)</td>
<td>(334)</td>
<td>75%</td>
<td>(332)</td>
<td>77%</td>
<td>(476)</td>
</tr>
<tr>
<td><strong>Profit before tax</strong></td>
<td>3 637</td>
<td>4 530</td>
<td>-20%</td>
<td>4 783</td>
<td>-24%</td>
<td>8 823</td>
</tr>
<tr>
<td>Tax</td>
<td>(618)</td>
<td>(802)</td>
<td>-23%</td>
<td>(847)</td>
<td>-27%</td>
<td>(1 450)</td>
</tr>
<tr>
<td><strong>Profit after tax</strong></td>
<td>3 019</td>
<td>3 728</td>
<td>-19%</td>
<td>3 936</td>
<td>-23%</td>
<td>7 373</td>
</tr>
<tr>
<td>NHEPS (cents)</td>
<td>680</td>
<td>816</td>
<td>-17%</td>
<td>862</td>
<td>-21%</td>
<td>1 628</td>
</tr>
<tr>
<td>Normalised effective tax rate</td>
<td>17.0%</td>
<td>17.7%</td>
<td></td>
<td>17.7%</td>
<td></td>
<td>16.4%</td>
</tr>
</tbody>
</table>

<sup>1</sup> CER removes the currency effect on performance: H1 2022 at H1 2023 average exchange rates.
## APPENDIX 3 | RECONCILIATION OF NHEPS

<table>
<thead>
<tr>
<th>Cents</th>
<th>H1 2023</th>
<th>H1 2022</th>
<th>% change</th>
<th>H1 2022 (CER(^1))</th>
<th>% change (CER(^1))</th>
<th>FY 2022</th>
</tr>
</thead>
<tbody>
<tr>
<td>Basic earnings per share (EPS)</td>
<td>602.0</td>
<td>736.2</td>
<td>-18%</td>
<td>782.1</td>
<td>-23%</td>
<td>1 432.3</td>
</tr>
<tr>
<td>Impairment of property, plant and equipment</td>
<td>0.3</td>
<td>-</td>
<td></td>
<td>0.3</td>
<td>-</td>
<td>1.9</td>
</tr>
<tr>
<td>Impairment of intangible assets</td>
<td>59.3</td>
<td>77.2</td>
<td></td>
<td>77.8</td>
<td>327.3</td>
<td>3.2</td>
</tr>
<tr>
<td>Impairment of right-of-use assets</td>
<td>-</td>
<td>-</td>
<td></td>
<td>-</td>
<td>-</td>
<td>2.4</td>
</tr>
<tr>
<td>Impairment of goodwill</td>
<td>-</td>
<td>1.7</td>
<td></td>
<td>1.7</td>
<td>-</td>
<td>(79.6)</td>
</tr>
<tr>
<td>Reversal of impairment of intangible assets</td>
<td>-</td>
<td>-</td>
<td></td>
<td>-</td>
<td>-</td>
<td>(2.5)</td>
</tr>
<tr>
<td>Reversal of impairment of property, plant and equipment</td>
<td>-</td>
<td>(1.3)</td>
<td></td>
<td>(1.3)</td>
<td>-</td>
<td>(252.6)</td>
</tr>
<tr>
<td>Profit on sale of assets classified as held-for-sale</td>
<td>-</td>
<td>-</td>
<td></td>
<td>-</td>
<td>-</td>
<td>(11.0)</td>
</tr>
<tr>
<td>Insurance compensation of assets</td>
<td>-</td>
<td>(9.1)</td>
<td></td>
<td>(9.7)</td>
<td>(39.8)</td>
<td></td>
</tr>
<tr>
<td>(Profit)/loss on sale of tangible and intangible assets</td>
<td>(0.7)</td>
<td>(27.8)</td>
<td></td>
<td>(27.8)</td>
<td>(39.8)</td>
<td></td>
</tr>
<tr>
<td><strong>Headline earnings per share (HEPS)</strong></td>
<td><strong>660.6</strong></td>
<td><strong>777.2</strong></td>
<td><strong>-15%</strong></td>
<td><strong>823.1</strong></td>
<td><strong>-20%</strong></td>
<td><strong>1 461.2</strong></td>
</tr>
<tr>
<td>Restructuring costs</td>
<td>3.6</td>
<td>9.0</td>
<td></td>
<td>9.6</td>
<td>29.7</td>
<td>124.1</td>
</tr>
<tr>
<td>Transactions costs</td>
<td>15.4</td>
<td>33.2</td>
<td></td>
<td>32.6</td>
<td>16.6</td>
<td></td>
</tr>
<tr>
<td>Product litigation costs</td>
<td>-</td>
<td>0.8</td>
<td></td>
<td>0.8</td>
<td>(3.3)</td>
<td></td>
</tr>
<tr>
<td>Reversal of deferred consideration no longer payable</td>
<td>-</td>
<td>(3.2)</td>
<td></td>
<td>(3.2)</td>
<td>(0.7)</td>
<td></td>
</tr>
<tr>
<td>Foreign exchange gain relating to acquisition</td>
<td>-</td>
<td>(0.6)</td>
<td></td>
<td>(0.6)</td>
<td>(0.7)</td>
<td></td>
</tr>
<tr>
<td><strong>Normalised HEPS</strong></td>
<td><strong>679.6</strong></td>
<td><strong>816.4</strong></td>
<td><strong>-17%</strong></td>
<td><strong>862.3</strong></td>
<td><strong>-21%</strong></td>
<td><strong>1 627.6</strong></td>
</tr>
</tbody>
</table>

\(^1\) CER removes the currency effect on performance. H1 2022 has been restated at H1 2023 average exchange rates.
NHEPS = 680 cents
NHEPS growth (Reported) = -17%
NHEPS growth (CER) = -21%
Share buy-back benefited NHEPS by +2%

1 CER removes the currency effect on performance. H1 2022 has been restated at H1 2023 average exchange rates.
2 Normalised EBITDA, depreciation, amortisation and net finance costs shown on a before-tax basis.
APPENDIX 5 | CURRENCY MIX

<table>
<thead>
<tr>
<th>Currency contribution</th>
<th>H1 2023</th>
<th></th>
<th>H1 2022</th>
<th></th>
<th>H1 2023</th>
<th>H1 2022</th>
<th>% change</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>Revenue</td>
<td>Normalised EBITDA</td>
<td>Revenue</td>
<td>Normalised EBITDA</td>
<td>Revenue average rate</td>
<td>Revenue average rate</td>
<td></td>
</tr>
<tr>
<td>EUR</td>
<td>27%</td>
<td>7%</td>
<td>29%</td>
<td>14%</td>
<td>17.57</td>
<td>17.44</td>
<td>1%</td>
</tr>
<tr>
<td>ZAR</td>
<td>16%</td>
<td>11%</td>
<td>17%</td>
<td>10%</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>AUD</td>
<td>16%</td>
<td>26%</td>
<td>14%</td>
<td>21%</td>
<td>11.61</td>
<td>10.99</td>
<td>6%</td>
</tr>
<tr>
<td>CNY</td>
<td>9%</td>
<td>20%</td>
<td>10%</td>
<td>22%</td>
<td>2.48</td>
<td>2.34</td>
<td>6%</td>
</tr>
<tr>
<td>USD</td>
<td>7%</td>
<td>(14%)</td>
<td>7%</td>
<td>(13%)</td>
<td>17.32</td>
<td>15.03</td>
<td>15%</td>
</tr>
</tbody>
</table>

- Except for the EUR and GBP, the ZAR has weakened against all its major trading currencies, providing a benefit to reported results compared to the CER performance.
- Lower EUR profit mix is attributable to the lower first half performance from Manufacturing operations in Europe and the loss of the J&J vaccine EUR revenue contribution.
- Strong performance in Australia has resulted in higher AUD contribution.
APPENDIX 6 | EFFECTIVE TAX RATES

- The year-on-year decrease in the Group effective tax rate is primarily due to a change in the mix of profits being generated by significant entities in the Group.
- Over the next two to three years Normalised effective tax rates expected to be in the range of 16% to 18%.
APPENDIX 7 | NET WORKING CAPITAL BRIDGE CER

R'MILLION

Fx impact FY 2022 CER

+8%
+R1 529

+R2 168

Commercial Pharma

Manufacturing

17 262
767
18 029
1 790
585
1 205
420
639
19 558

FY 2022 Reported
Fx impact
FY 2022 CER
Inventory
Trade receivables
Trade payables
Receivables/payables
Non cash
H1 2023

Cash Outflow

8%

+R1 529

\[ R'MILLION \]

\[ \text{CER removes the currency effect on performance. FY 2022 restated at H1 2023 year end exchange rates.} \]
### APPENDIX 8 | OPERATING CASH FLOW

**R’MILLION**

<table>
<thead>
<tr>
<th></th>
<th>H1 2023</th>
<th>H1 2022</th>
<th>% change</th>
<th>FY 2022</th>
</tr>
</thead>
<tbody>
<tr>
<td>Cash operating profit</td>
<td>5 312</td>
<td>5 263</td>
<td>1%</td>
<td>10 023</td>
</tr>
<tr>
<td>Changes in working capital</td>
<td>(2 168)</td>
<td>(2 301)</td>
<td>6%</td>
<td>(2 652)</td>
</tr>
<tr>
<td><strong>Cash generated from operations</strong></td>
<td><strong>3 144</strong></td>
<td><strong>2 962</strong></td>
<td>6%</td>
<td><strong>7 371</strong></td>
</tr>
<tr>
<td>Net finance costs paid</td>
<td>(500)</td>
<td>(290)</td>
<td>72%</td>
<td>(306)</td>
</tr>
<tr>
<td>Tax paid</td>
<td>(937)</td>
<td>(911)</td>
<td>3%</td>
<td>(1 691)</td>
</tr>
<tr>
<td><strong>Cash generated from operating activities</strong></td>
<td><strong>1 707</strong></td>
<td><strong>1 761</strong></td>
<td><strong>-3%</strong></td>
<td><strong>5 374</strong></td>
</tr>
<tr>
<td><strong>Operating cash flow per share (cents)</strong></td>
<td><strong>384</strong></td>
<td><strong>386</strong></td>
<td><strong>0%</strong></td>
<td><strong>1 186</strong></td>
</tr>
</tbody>
</table>

**Operating cash conversion rate***

<p>| | |</p>
<table>
<thead>
<tr>
<th></th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>58%</td>
</tr>
</tbody>
</table>

- The increased investment in Manufacturing inventory in H1 2023 has reduced the growth in cash generated from operations.
- Foreign exchange losses increase net finance costs paid.
- Seasonal operating cash flow conversion rate cycle which follows a recurring trend. Manufacturing inventory levels expected to substantially unwind in H2 2023. Operating cash conversion rate is targeted to exceed 100% by financial year end.

---

*Operating cash conversion rate = operating cash flow per share/HEPS.*
Capital expenditure excludes interest on the cost of funding capitalised to projects.

* Bolt-on acquisitions and disposals are limited to a net transaction value of R1 billion per annum.

**Steriles capacity expansion project progressing well and line 3 is expected to be operational by Sept 2023 with the completion dates of lines 4 and 5 scheduled for Dec 2023 and Sept 2024 respectively**

* The rehabilitation of the Alphamed site in India was completed in H1 2023 and has been inspected and approved by SAPHRA

**Comprises in-house product development and IT projects**

* Digitalisation projects totalling R720m continue to be the main contributor to the total planned spend in FY 2023
* Total planned spend including IP development projects is R1.2 billion
* Excludes net bolt-on acquisitions/disposals*

---

**APPENDIX 9 | CAPITAL EXPENDITURE**

### PPE Capex in R’million

- **FY 2021**: 2,045
- **FY 2022**: 1,963
- **H1 2023**: 836
  - Actual Capex: 706
  - Sterile expansion: 130
- **FY 2023**: 2,300
  - Actual Capex: 1,600
  - Planned: 700
- **FY 2024**: 2,400
  - Actual Capex: 1,600
  - Planned: 800
During November 2022, the Group entered into new EUR, ZAR and AUD syndicated bank debt facilities (“New Facilities”) and settled an existing R8.4 billion syndicated bank debt which was included in current borrowings in the June 2022 AFS.

The net effect of the settlement of the facilities due in this period resulted in no gross in/ outflows in the Statement of Cash Flows.

The New Facilities mature on dates ranging from 30 November 2025 to 30 November 2026 with the option to extend these maturities through to November 2028.

Aspen has been selected as the winner of this year’s Bonds, Loans & ESG Capital Markets Africa Award for Syndicated Loan Deal of the Year.

Oss loan owing to MSD of EUR 188 million due for repayment in September 2023 is excluded from net borrowings but is included in the leverage ratio calculation.

### Net Borrowings in R’million

<table>
<thead>
<tr>
<th>Period</th>
<th>Current Borrowings</th>
<th>Non-Current Borrowings</th>
<th>Cash</th>
</tr>
</thead>
<tbody>
<tr>
<td>H1 2022</td>
<td>19 912</td>
<td>7 274</td>
<td>-7 876</td>
</tr>
<tr>
<td>FY 2022</td>
<td>19 912</td>
<td>11 665</td>
<td>-6 183</td>
</tr>
<tr>
<td>H1 2023</td>
<td>18 751</td>
<td>4 827</td>
<td>-8 045</td>
</tr>
</tbody>
</table>

*Current borrowings + non-current borrowings – cash.
# DEFERRED CONSIDERATION PAYMENTS

<table>
<thead>
<tr>
<th>R'million</th>
<th>H1 2023</th>
</tr>
</thead>
<tbody>
<tr>
<td>Disposal of the European Thrombosis assets – volume incentive payments and other transaction costs</td>
<td>370</td>
</tr>
<tr>
<td>Disposal of Japanese business – supply rebate payments</td>
<td>73</td>
</tr>
<tr>
<td>Other</td>
<td>41</td>
</tr>
<tr>
<td><strong>Total</strong></td>
<td><strong>484</strong></td>
</tr>
</tbody>
</table>